Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09989 Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
84 GF Score
Price HK$4.16
GF Value HK$4.71
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

HKSE:09989
84GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of HK$4.16 is trading 11.8% below its estimated GF Value™ of HK$4.71. GuruFocus considers Shenzhen Hepalink Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for HKSE:09989:

  • Dividends Received:
  • GF Value™: HK$4.71 vs. price of HK$4.16 (11.8% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the HKSE:09989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
84GF Score

Get the complete analysis for HKSE:09989

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.16
Price
HK$4.71
GF Value